LGND FY 2022 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

LGNDLigand Pharmaceuticals Incorporated

$4B

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$196M-18.8% YoY

Gross Profit

$143M73.1% margin

Operating Income

$3M1.5% margin

Net Income

-$33M-17.0% margin

EPS (Diluted)

$-1.98

Cash Flow

Operating Cash Flow

$138M

Free Cash Flow

$120M

Stock-Based Comp.

$60M

Balance Sheet

Total Assets

$763M

Total Liabilities

$165M

Stockholders' Equity

$597M

Cash & Equivalents

$45M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$196M	$242M	-18.8%
Gross Profit	$143M	$179M	-20.0%
Operating Income	$3M	$104M	-97.1%
Net Income	-$33M	$57M	-158.4%